Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Marubeni Pharma Sets Up Hong Kong Subsidiary
Marubeni Pharmaceuticals said on September 1 that it established a wholly owned subsidiary in Hong Kong on August 19 to handle the import, sales, and marketing of pharmaceutical products in the territory.The new unit, Marubeni Pharmaceuticals Hong Kong Limited, will…
To read the full story
Related Article
BUSINESS
- GSK Hit with MHLW Guidance over Sponsored Lecture
September 2, 2026
- Nonprescription Cialis Goes Nationwide in Japan, Now at 10,000 Outlets
September 2, 2026
- Veloxis Starts US PII Study of Novel Immunosuppressant
September 2, 2026
- Canada Backs Public Reimbursement of Leqembi
September 2, 2026
- Marubeni Pharma Sets Up Hong Kong Subsidiary
September 2, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…